Natalizumab

4 trials 1 recruiting LOncology

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

3 Completed trials

4 Sponsors

4 Countries

Phase II

Phase IV

Phase II: 3 Phase IV: 1

Indications tested

Multiple sclerosis 1 Secondary progressive multiple sclerosis 1 Relapsing-remitting multiple sclerosis 1 Progressive multiple sclerosis 1 Primary progressive multiple sclerosis 1

Sponsors using this IMP

Amsterdam UMC Stichting 1 Antwerp University Hospital 1 Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S 1 Helse Bergen HF 1

All trials

4 total

No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis Recruiting

2024-515470-26-00 Phase II 1 country Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S
Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS) Ended

2024-513105-31-00 Phase IV 1 country Amsterdam UMC Stichting
Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placeb… Ended

2023-503190-38-00 Phase II 1 country Antwerp University Hospital
The TAF-MS study Ended

2023-503814-62-00 Phase II 1 country Helse Bergen HF

Showing 1–4 of 4 trials

← All drugs A–Z